In March 2026, Meiji Seika Pharma Co., Ltd. reported that its selective PDE4 inhibitor morcamilast (development code ME3183; proposed international nonproprietary name) has received orphan medicinal ...
The orphan drugs market is seeing strong expansion, propelled by the growing worldwide incidence of genetic conditions and other rare diseases, as well as the substantial unmet need for effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results